早期特异性IgE变化可预测舌下免疫治疗满意度
结果发现基线免疫指标组间无差异,但早期Dp和Df特异性IgE变化在不满意组显著更高,提示早期IgE变化可预测长期疗效。
要点
- 基线免疫指标不能预测SLIT长期满意度
- 治疗1年时Dp和Df特异性IgE变化与3年满意度相关
- 不满意组早期特异性IgE变化显著高于满意组
核心结论
- 早期Dp和Df特异性IgE水平变化可能是SLIT长期治疗结果的指标。
- 临床可在SLIT1年后检测这些免疫指标以区分潜在应答者与非应答者。
研究设计与样本
- 基线及1年随访时进行血清学检测,3年后评估满意度、4项鼻部症状和生活质量。
主要发现
- 43例(70.5%)对SLIT满意,18例(29.5%)不满意。
- 基线免疫参数在满意组与不满意组间无显著差异。
- 早期SLIT应答期间,不满意组的Dp特异性IgE变化显著高于满意组(P = .006)。
- 早期SLIT应答期间,不满意组的Df特异性IgE变化显著高于满意组(P = .045)。
关键数值与推荐
- SLIT治疗至少3年。
- 基线及1年随访时进行血清学检测。
- 3年后评估满意度、4项鼻部症状和生活质量。
临床怎么用
- 临床可在尘螨SLIT治疗1年后检测Dp和Df特异性IgE变化,辅助判断潜在应答者与非应答者。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate predictive parameters at baseline and during the early response to sublingual immunotherapy (SLIT) for house dust mites in allergic rhinitis patients. STUDY DESIGN: Retrospective cohort study. METHODS: Patients were treated with SLIT for at least 3 years and serological tests performed at baseline and at 1-year follow-up to investigate predictive parameters. Satisfaction with SLIT, 4 nasal symptoms, and quality of life were evaluated before and after 3 years of SLIT. Sixty-one patients were enrolled and divided into two groups depending on their satisfaction after 3 years of SLIT: 43 were satisfied (70.5%) and 18 were not (29.5%). RESULTS: Immunological parameters at baseline did not differ significantly between the satisfactory and unsatisfactory groups. However, changes in both Dermatophagoides pteronyssinus (Dp)- and D. farinae (Df)-specific IgEs were significantly higher in the unsatisfactory group than in the satisfactory group during the early response to SLIT (P = .006 and P = .045, respectively). CONCLUSION: The changes in both Dp- and Df-specific IgE levels during early response may be indicators for favorable long-term treatment outcomes with SLIT. These results suggest that clinicians could measure these immunological parameters 1 year after Dp and Df SLIT to indicate potential responders versus nonresponders. LEVEL OF EVIDENCE: 2b Laryngoscope, 131:467-472, 2021.
引用
- Kim JY, Rhee CS, Mun SJ, et al. Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy. Laryngoscope. 2020. PMID: 32562508. doi:10.1002/lary.28762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。